• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Hepion Pharmaceuticals

two arrows pointing different ways
Biotech

Merger for troubled liver disease biotech called off

Hepion and Pharma Two B have terminated a merger that was expected to close by the end of the year.
Gabrielle Masson Dec 11, 2024 12:43pm
MA strategy deal block push come together form

In struggling Hepion, Israeli biotech spies path to go public

Jul 22, 2024 9:14am
parachute chutes

BIO announces new CEO—Chutes & Ladders

Dec 8, 2023 9:30am
balance tightrope risk

Hepion’s NASH trial hangs in balance amid cost-cutting, CEO exit

Dec 7, 2023 11:38am
Liver disease

Hepion shares midphase NASH data ahead of key clinical readout

May 22, 2023 7:00am
Gloved hands putting together a liver out of puzzle pieces

Hepion NASH drug clears safety bar, ready for phase 2b

Jul 13, 2021 10:20am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings